Cite
HARVARD Citation
Li, J. et al. (2022). Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial. Thoracic cancer. 13 (24), pp. 3496-3503. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Li, J. et al. (2022). Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial. Thoracic cancer. 13 (24), pp. 3496-3503. [Online].